Molnupiravir (EIDD-2801) is an innovative antiviral agent developed for oral administration, designed to combat viral infections effectively. This compound, known by its alternative name EIDD-2801, is formulated as tablets, making it convenient for patients to take the medication orally. With a CAS number of 2349386-89-40, Molnupiravir (EIDD-2801) has garnered significant attention in the pharmaceutical and medical communities due to its promising therapeutic potential.
The primary mode of administration for Molnupiravir (EIDD-2801) is oral, which allows for ease of use and better patient compliance compared to injectable antivirals. The tablet form ensures accurate dosing and stability, facilitating consistent treatment regimens. This attribute is especially important for managing viral diseases that require timely and precise dosing schedules to maximize efficacy.
Molnupiravir (EIDD-2801) exhibits a unique mechanism of action that interferes with the replication of viral RNA, thereby inhibiting the proliferation of viruses within the host. This mechanism makes it a valuable candidate for treating a range of viral infections, including those caused by RNA viruses. Its broad-spectrum antiviral activity highlights its potential role in addressing emerging viral threats and pandemics.
Storage conditions for Molnupiravir (EIDD-2801) are critical to maintaining its stability and effectiveness. It is recommended to store this product at controlled room temperature, specifically between 20-25°C (68-77°F). Proper storage ensures that the tablets retain their potency and safety throughout their shelf life, preventing degradation that could compromise therapeutic outcomes.
As an orally administered antiviral in tablet form, Molnupiravir (EIDD-2801) offers several advantages, including ease of distribution, patient-friendly administration, and reduced need for medical supervision during treatment. These features make it particularly suitable for outpatient care and rapid deployment in public health scenarios where quick response to viral outbreaks is essential.
The development of Molnupiravir (EIDD-2801) represents a significant advancement in antiviral therapy, providing a novel option for clinicians to combat viral infections effectively. Its chemical identity as EIDD-2801 and CAS number 2349386-89-40 allow for precise identification and standardized quality control in pharmaceutical manufacturing and research settings.
In summary, Molnupiravir (EIDD-2801) is a clinically important antiviral agent delivered in tablet form for oral administration. Its recommended storage at controlled room temperature ensures optimal stability and efficacy. With its unique antiviral properties and convenient dosage form, Molnupiravir (EIDD-2801) continues to be a vital component in the fight against viral diseases, offering hope for improved patient outcomes worldwide.
Molnupiravir (EIDD-2801), marketed under the brand name FIPNOPE, is an innovative antiviral medication originating from China. This product is specifically formulated as tablets, each containing the active compound with the chemical formula C13H19N3O7. Designed for the treatment of COVID-19, Molnupiravir (EIDD-2801) provides a vital therapeutic option in managing this global health challenge.
The primary application occasion for Molnupiravir (EIDD-2801) is in clinical settings where patients are diagnosed with COVID-19. It is suitable for use in hospitals, clinics, and healthcare centers where rapid intervention is necessary to reduce viral load and prevent disease progression. Given its oral dosage form, it is especially convenient for outpatient treatment, allowing patients to continue their recovery at home under medical supervision.
Molnupiravir (EIDD-2801) is also highly relevant in scenarios involving early-stage COVID-19 infection. Administering this antiviral drug promptly after diagnosis can significantly improve patient outcomes by inhibiting viral replication. This makes it an essential medication in pandemic response plans, quarantine facilities, and during outbreaks in community health programs. Additionally, it can be used in high-risk populations such as the elderly or those with underlying health conditions to mitigate severe disease development.
The product’s packaging details—10 tablets per plate—facilitate easy dispensing and dosage management. With a minimum order quantity of 50 tablets and a competitive price range of US$1.5 to US$2.1 per tablet, it is accessible for hospitals and pharmacies aiming to maintain sufficient stock. The supply ability of 50,000 vials per month ensures consistent availability to meet market demand.
In terms of storage and handling, Molnupiravir (EIDD-2801) must be stored at controlled room temperature between 20-25°C (68-77°F), ensuring stability and efficacy during transportation and storage. Delivery time is efficient, typically within 7-10 days, supporting timely distribution. Payment terms are flexible, accepting T/T, Western Union, MoneyGram, and Paypal, accommodating various purchasing preferences.
Overall, Molnupiravir (EIDD-2801) by FIPNOPE serves as a critical antiviral agent in the fight against COVID-19, suitable for diverse application occasions and scenarios including hospital treatment, outpatient care, early intervention, and pandemic control efforts worldwide.
For technical support and services related to Molnupiravir (EIDD-2801), please refer to the detailed product documentation and user manuals provided with your purchase. Our support team is available to assist with product usage, troubleshooting, and any technical inquiries to ensure optimal performance and satisfaction.
We offer comprehensive services including consultation on product applications, guidance on proper storage and handling, and assistance with compliance and regulatory information. For research and development purposes, detailed protocols and data sheets can be provided upon request.
Ensure that all usage complies with local regulations and guidelines. For any issues or further information, please utilize the support resources available on our official website or through authorized distributors.
Product Packaging and Shipping for Molnupiravir (EIDD-2801)
Molnupiravir (EIDD-2801) is carefully packaged to ensure product integrity and safety during transportation. The product is typically supplied in airtight, tamper-evident containers to protect it from moisture, light, and contamination.
For shipping, Molnupiravir is packed in sturdy, insulated packaging materials to maintain stable temperature conditions, as required. The product is shipped using reliable courier services with tracking options to guarantee timely and secure delivery.
All shipments comply with international shipping regulations for pharmaceutical products, including proper labeling and documentation to facilitate customs clearance and safe handling.
Q1: What is the brand name of Molnupiravir (EIDD-2801)?
A1: The brand name of Molnupiravir (EIDD-2801) is FIPNOPE.
Q2: Where is FIPNOPE Molnupiravir manufactured?
A2: FIPNOPE Molnupiravir is manufactured in China.
Q3: What is the minimum order quantity for FIPNOPE Molnupiravir?
A3: The minimum order quantity is 50 tablets.
Q4: How much does FIPNOPE Molnupiravir cost?
A4: The price ranges from US$1.5 to US$2.1 per tablet.
Q5: What are the packaging details for FIPNOPE Molnupiravir?
A5: The product is packaged as 10 tablets per plate.
Q6: What is the delivery time for orders of FIPNOPE Molnupiravir?
A6: The delivery time typically ranges from 7 to 10 days.
Q7: What payment methods are accepted for purchasing FIPNOPE Molnupiravir?
A7: Accepted payment methods include T/T, Western Union, MoneyGram, and Paypal.
Q8: What is the monthly supply capacity for FIPNOPE Molnupiravir?
A8: The supply ability is 50,000 vials per month.
